CBU
IBB icon

CIBC Bank USA’s iShares Biotechnology ETF IBB Stock Holding History

CIBC Bank USA’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,235
Closed -$248K – 276
2017
Q3 		$248K Sell
2,235
-315
-12% -$33.7K 0.03% 224
2017
Q2 		$263K Buy
+2,550
New +$251K 0.04% 220

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CIBC Bank USA's IBB Position: Q4 2017 in Review

CIBC Bank USA sold out of iShares Biotechnology ETF (IBB) in Q4 2017, closing a stake of 2,235 shares — an estimated $248K sold.

CIBC Bank USA first reported a position in IBB in Q2 2017 and held it in 2 quarters. The position peaked at $263K in Q2 2017. 624 funds tracked by Wall St. Rank hold IBB as of Q4 2017.

  • CIBC Bank USA reported no remaining iShares Biotechnology ETF position as of Q4 2017 after selling out during the quarter.
  • CIBC Bank USA sold 2,235 iShares Biotechnology ETF shares in Q4 2017, an estimated $248K.
  • CIBC Bank USA first reported a position in iShares Biotechnology ETF in Q2 2017 and held it in 2 quarters.
  • CIBC Bank USA's iShares Biotechnology ETF position peaked at $263K in Q2 2017.
  • 624 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2017.

Based on CIBC Bank USA's 13F filing for Q4 2017, filed 19 Jan 2018.